Dr Peter Traber joins Pro-Pharmaceuticals as president and CEO

Pro-Pharmaceuticals, a US-based company focused on the development of therapeutics that target Galectin receptors to treat cancer and fibrosis, has appointed Dr Peter Traber president and chief executive officer. He succeeds Dr Theodore Zucconi, who will continue as a member of the board of directors. Dr Traber has been interim chief medical officer since June 2010 and a member of the board of directors since February 2009. He is president emeritus of Baylor College of Medicine, and from 2003-08 was its CEO. Before that, he was senior vice-president of clinical development and medical affairs and chief medical officer at GlaxoSmithKline.

Pro-Pharmaceuticals, a US-based company focused on the development of therapeutics that target Galectin receptors to treat cancer and fibrosis, has appointed Dr Peter Traber president and chief executive officer. He succeeds Dr Theodore Zucconi, who will continue as a member of the board of directors. Dr Traber has been interim chief medical officer since June 2010 and a member of the board of directors since February 2009. He is president emeritus of Baylor College of Medicine, and from 2003-08 was its CEO. Before that, he was senior vice-president of clinical development and medical affairs and chief medical officer at GlaxoSmithKline.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

Boehringer Ingelheim Expects Two Key Approvals In Second Half Of 2025

 

The privately held German pharma firm is hoping to bring a new generation of pulmonary fibrosis and cancer drugs to market but their commercial success is not yet a certainty.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.

Genentech Gets Columvi Complete Response Following ODAC’s No

 
• By 

Seeking to move Columvi into second-line DLBCL, Genentech got an FDA letter saying the Phase III STARGLO study’s benefits may have been driven by results in Asian enrollees.

More from Therapeutic Category

Leo Looks To Grow In US After Hand Eczema Cream Approval

 
• By 

The Danish medical dermatology specialist doubles boosts its sales force ahead of the launch of Anzupgo.

Obesity Beyond GLP-1s: Amylins – The Next Frontier

 
• By 

In this series of articles, we look at different mechanisms of actions beyond GLP-1s that could determine the obesity drug landscape in the coming years. First on our list – amylin receptor agonists, which analysts expect to grow into a $50bn market opportunity.

Dispatch Uses ‘Flare’ To Send CAR-Ts To Solid Tumors

 

With $216m in initial funding, the newly launched company is aiming to develop a cell therapy-based universal immuno-oncology option for solid tumor indications.